Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma

Publication Date: January 6, 2021

Key Points

Key Points

  • Nasopharyngeal carcinoma (NPC) is uncommon in many jurisdictions but remains a significant public health problem in East and Southeast Asia, which accounted for more than 70% of the approximate 129,000 new diagnoses worldwide in 2018.
  • NPC relies almost exclusively on (chemo-)radiotherapy to achieve disease control in most presentations, particularly in the definitive treatment of stage II to IVA disease.

Treatment

...eatment...

...: For Patients with Stage II to IVA Naso...

...1.1For all nasopharyngeal carcinoma (NPC) pa...

....2For all NPC patients, both sequen...

...endation 1.3For all NPC patients, a prescribed dos...

....4For all NPC patients, gross tumor volume shou...

...ecommendation 1.5For NPC patients who have u...

...1.6The delineation of elective nodal volumes...


...erapy Sequence

...ommendation 2.1For T2N0 (AJCC 8th)...

...on 2.2For T1-2N1 (AJCC 8th) NPC pati...

...ommendation 2.3For Stage III–IVA (except...

...dation 2.4For Stage III–IVA (except T3N0...

....5For T3N0 (AJCC 8th) NPC patients, concurrent...


...rrent Chemotherapy...

...ion 3.1For all NPC patients without contraindic...

Recommendation 3.2For all NPC patients...

...ommendation 3.3For NPC patients with a contr...

...ndation 3.4For NPC patients with a contraindi...


...tion Chemotherapy...

...endation 4.1For all NPC patients recei...

...ndation 4.2For NPC patients receiving induction ch...

...mmendation 4.3For NPC patients receiving...


...vant Chemothera...

...endation 5.1For all NPC patients rec...

...endation 5.2For all NPC patients receiving adj...

...ion 5.3For all NPC patients receiv...


...igure 1. Stage II to IVA Nasopharyngeal C...